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Abstract 27 
Study design: Review Study 28 
Objectives: The identification of prognostic biomarkers of SCI will help to assign SCI patients to the 29 
correct treatment and rehabilitation regimes. Further, the detection of biomarkers that predict 30 
permanent neurological outcome would aid appropriate recruitment of patients into clinical trials. 31 
The objective of this review is to evaluate the current state-of-play in this developing field. 32 
Setting: Studies from multiple countries were included. 33 
 34 
Methods: We have completed a comprehensive review of studies that have investigated prognostic 35 
biomarkers in either the blood or CSF of animals and humans following SCI.  36 
 37 
Results: Targeted and unbiased approaches have identified several prognostic biomarkers in CSF 38 
and blood. These proteins associate with cellular damage following SCI and include components 39 
from neurons, oligodendrocytes and reactive astrocytes, i.e. neurofilament proteins, glial fibrillary 40 
acidic protein, Tau, and S100 calcium binding protein β. Unbiased approaches have also identified 41 
microRNAs that are specific to SCI, as well as other cell damage associated proteins. 42 
 43 
Conclusions: The discovery and validation of stable, specific, sensitive and reproducible biomarkers 44 
of SCI is a rapidly expanding field of research. To date, few studies have utilised unbiased 45 
approaches aimed at the discovery of biomarkers within the CSF or blood in this field, however some 46 
targeted approaches have been successfully used. Several studies using various animal models and 47 
some with small human patient cohorts have begun to pinpoint biomarkers in the CSF and blood with 48 
putative prognostic value. An increased sample size will be required to validate these biomarkers in 49 
the heterogeneous clinical setting. 50 
Keywords 51 
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1. Introduction 53 
There is now a vast and expanding body of literature describing different novel approaches for the 54 
treatment of spinal cord injury (SCI). Despite this, actions to treat and rehabilitate following SCI 55 
have not changed. Outside of clinical trials, SCI is typically managed either by surgical stabilisation 56 
or conservative management in the acute and subacute setting, followed by physiotherapy in the 57 
subacute and chronic phases of injury (1,2). It is clear that the SCI research field as a whole is 58 
experiencing a significant delay in the translation of new interventions into the clinic. There are 59 
many valid reasons why scientists and clinicians alike are cautious to translate new therapies into 60 
humans, particularly as setting up appropriate clinical trials to demonstrate safety and efficacy can be 61 
difficult (3). 62 
 63 
There is a growing appreciation for the benefit of using biomarkers to help introduce new treatments 64 
and improve strategies of care for SCI patients. We suggest there are several ways (diagnostic, 65 
prognostic and therapeutic) in which measuring biomarkers in the blood or CSF might complement 66 
current clinical measures, such as the American Spinal Injuries Association (ASIA) International 67 
Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) scoring system and 68 
assessment of dry biomarkers such as magnetic resonance imaging (MRI) scans, to further the SCI 69 
field. Together a panel of biomarkers and neurological tests perhaps even including 70 
electrophysiological assessments may provide clinicians with a much clearer picture as to an 71 
individuals’ severity of neurologic impairment. 72 
 73 
Predicting neurologic recovery based on the AIS grade assigned immediately following SCI is 74 
challenging (4,5). For patients, knowing whether they will regain the ability to walk, irrespective of 75 
neurological, bladder or bowel function improvement, remains their key concern (6). Identification 76 
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of a panel of biomarkers that could accurately predict an individuals’ ability to regain neurological, 77 
physical and autonomic function, could be of great psychological benefit to these patients. 78 
Furthermore, depending on the individuals’ prognosis, the treatment pathway could be tailored to 79 
ensure that optimal neurological and/or physical function is regained and that patient rehabilitative 80 
care is maintained until their best possible outcome is achieved.  81 
 82 
ISNCSCI diagnosis of a SCI can be delayed due to problems associated with poly-trauma 83 
stabilisation or a lack of SCI expertise at the treating hospital. Therefore a diagnostic CSF or blood 84 
test that can be used to assess the neurological state of these individuals may provide a quicker, 85 
cheaper and more accurate method, which will empower clinicians to stratify patients to the most 86 
suitable treatments for their needs. Additionally, as novel treatments to target the acute phase of SCI 87 
develop, quick and accurate diagnoses of patients who will be appropriate to recruit to these clinical 88 
trials will ensure studies are appropriately powered to assess efficacy. Despite prediction of 89 
neurological improvement having been the focus of a majority of biomarker studies, there is also 90 
value in the use of biomarkers to predict other long-term outcomes, such as neuropathic pain, for 91 
which early intervention studies could be implemented to try and prevent the onset of these 92 
conditions. 93 
 94 
Currently, in both routine clinical care and in clinical trials, the neurological condition of individuals 95 
is assessed by ISNCSCI grading and imaging modalities. Biomarkers that can easily be repeatedly 96 
measured within the blood or CSF of these individuals’ to determine progressive neurological 97 
condition would be highly beneficial, as it would allow rapid determination as to whether the patient 98 
was improving, worsening or showed sustained neurological stability in response to their current 99 
treatment; thus providing a biological surrogate outcome measure. Further, such biomarkers might 100 
indicate whether the patient has increased neurological plasticity in response to a treatment or 101 
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rehabilitation regime. Finally, biomarkers released into the CSF and or blood, may provide a plethora 102 
of information as to the patients’ biological response to SCI. As discussed below, different biological 103 
responses to SCI may lead to specific molecules being released into the CSF or blood; these fluids 104 
may contain a unique fingerprint that can be used by scientists and clinicians to elucidate the 105 
mechanisms underlying an individuals’ SCI.  Again, this could allow for personalised treatments to 106 
be provided to a patient that target their specific injury mechanisms and that can be used to assess 107 
their specific mechanistic responses. 108 
 109 
In recent years, scientists have started to take up the challenge of discovering and validating 110 
biomarkers in the blood and CSF that have prognostic value in accurately diagnosing complete or 111 
incomplete SCI and determining SCI progression. This review aims to present an overview of the 112 
current state of play in this emerging field. We will explain how the biological process of SCI may 113 
lead to the release of biomarkers of interest into the CSF and blood; the techniques that are 114 
commonly used to find and validate these markers, and the pre-clinical and clinical studies that have 115 
already begun to highlight biomarkers of interest. 116 
 117 
2. SCI and the release of biochemical biomarkers 118 
This section of the review aims to highlight some of the major processes that occur following a SCI, 119 
which could lead to biomarker release. It is still unclear how biomarkers from the spinal cord are 120 
released into the blood following injury; however, we suggest that their release is likely to be highly 121 
influenced by the specific type of injury sustained and the biochemical properties of the biomarkers 122 
in question. The majority of biomarkers which have already been studied in both pre-clinical and 123 
clinical studies have been identified from targeted biomarker identification processes, i.e. looking for 124 
markers that are likely released based on the known biological processes/mechanisms that occur 125 
following SCI.  126 
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 127 
2.1. Spinal cord tissue damage 128 
In both animal models of SCI and in the human situation, spinal cord traumas fall broadly into two 129 
categories: transection injuries, where the spinal cord is penetrated with a sharp force; and the more 130 
common contusion traumas, where the spinal cord is essentially crushed (7,8). Both types of injury 131 
result in a breach of the blood brain barrier (BBB) and either immediate primary or secondary 132 
damage to the neurons and glia of the spinal cord tracts. Rupture of these cell types results in the 133 
release of biomarkers, largely cellular components, which are specific in the indication of nervous 134 
tissue damage and include neurofilaments (NF) (9), Tau (10), neuron specific enolase (NSE) (11), 135 
S100 calcium-binding protein β (S100β) (11) and glial fibrillary acidic protein (GFAP) (9). These 136 
tissue specific biomarkers (discussed in greater detail below) hold great promise as they are typically 137 
released into the CSF then taken up into the blood stream, allowing for their detection local to the 138 
injury site and systemically. The quantity of these proteins in the CSF and blood might directly relate 139 
to the extent of neuronal or glial damage that has occurred following SCI (12,13).  140 
 141 
2.2 Inflammation  142 
In brief, the breakdown of the BBB allows for an influx of inflammatory cells into spinal cord 143 
tissues. Infiltrating leukocytes and resident microglia release proteolytic and oxidative enzymes, 144 
reactive oxygen species and an array of pro-inflammatory cytokines, including, for example, tumour 145 
necrosis factor-alpha (TNF-α) (14,15). This spike in acute phase pro-inflammatory molecules can be 146 
measured in human blood in the first 24h following injury (16). Caution must be taken when 147 
considering the blood at this stage however, as many of the abundant proteins that are seen acutely 148 
after injury may be a result of the systemic response to trauma and not SCI per se; study of animal 149 
models where matched ‘sham’ injuries can be performed allows for the opportunity to establish 150 
which proteins are SCI specific. The pronounced acute pro-inflammatory response to injury induces 151 
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a reactive process of secondary damage in the tissues that surround the original injury site, 152 
exacerbating neuronal damage and neurological dysfunction (14). This secondary damage cascade 153 
can continue for several weeks following SCI, contributing to an expanding matrix of proteins 154 
associated with neuronal and glial cell apoptosis, such as soluble CD95 ligand (sCD95L), an initiator 155 
of the Fas apoptotic pathway (17). 156 
 157 
2.3 Glial scarring 158 
Glial cell activation and hypertrophy leads to the formation of a glial scar in the subacute and chronic 159 
phases of SCI (18). Astrocytes become reactive and synthesise an extracellular matrix which is 160 
effective in restoring the BBB, but that coincidentally inhibits axonal regrowth (18). The most potent 161 
of these astrocyte associated nerve inhibitory molecules are the neural chondroitin sulphated 162 
proteoglycans (CSPGs) (19,20). Myelin damage associated molecules represent the other major 163 
nerve inhibitory molecules within the glial scar, these include myelin-associated glycoprotein 164 
(MAG), Nogo-A and oligodendrocyte-myelin glycoprotein (OMgp) (21). There is a vast body of 165 
literature which confirms that CSPGs, MAG, Nogo-A and OMgp can inhibit neurite outgrowth in 166 
vitro and axonal regrowth in vivo (22–28) and that treatments which specifically target these 167 
molecules promote functional recovery in SCI pre-clinical studies both individually (29,30) and in 168 
combination (31). However, there is little research exploring the utility of these molecules as 169 
prognostic biomarkers detectable in the CSF (32). Perhaps this is because we associate such 170 
molecules with the subacute or chronic phases of injury, when a stable neurology is much more 171 
likely. However, biomarkers, such as CPSGs that could be used to monitor any transition from the 172 
sub-acute to chronic phase of injury might aid clinicians in decisions regarding rehabilitation. 173 
 174 
3. Detection of biomarkers for SCI using unbiased approaches 175 
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Although it would be ideal, biomarkers of injury or disease are rarely either “detectable” or 176 
“undetectable”. In most cases, biomarkers vary in expression levels under different conditions. It is 177 
important, therefore, to have specific and sensitive methods to quantify these changes. Typically, 178 
immunoassays have been the method of choice for studies that aimed to evaluate SCI biomarkers 179 
within the blood or CSF. The enzyme-linked immunosorbent assay (ELISA) is the most commonly 180 
employed assay to date, and both homemade and commercial ELISA kits have been utilised. 181 
Automated immunoassay systems are available for some potential biomarkers e.g. the Liaison 182 
automatic analyser for S100β and NSE (9,33), but it seems unlikely that the use of automated 183 
systems will become widespread until such biomarkers have become fully validated for routine 184 
clinical use. 185 
 186 
The vast majority of studies aimed at finding new biomarkers for SCI have been based on a 187 
hypothesis about a particular protein of interest. Shaw et al. (2005), for example, proposed that, due 188 
to their high abundance in neurons, detection of NF proteins in CSF and/or serum is highly likely to 189 
indicate neuronal damage (34). Of the three NF subunits (i.e. light (L), medium (M) and heavy (H)), 190 
phosphorylated NF-H (pNF-H) was thought likely to be the most readily detectable in serum or CSF 191 
following neurological injury because of its relative resistance to protease degradation (34). The 192 
results from this hypothesis-driven study formed the basis of several further studies to evaluate the 193 
prognostic potential of this biomarker following SCI (9,35). 194 
 195 
Surprisingly very few studies, however, have employed higher-throughput techniques to identify new 196 
biomarkers of SCI. A search of PubMed using the terms “proteomics AND spinal cord injury” and 197 
“biomarkers AND spinal cord injury” identified just four publications in which the aim of the study 198 
was to identify new peripherally accessible biomarkers of SCI (Table 1). Even more surprisingly, 199 
given the popularity in other fields of biomedical research (recently reviewed by Crutchfield et al. 200 
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(2016) (36)), only two of these studies reported the use of unbiased quantitative proteomic techniques 201 
to find novel biomarkers of SCI in the CSF or blood, while the remaining two studies employed 202 
relatively low-throughput array technology. Notwithstanding the limitations of array technology-203 
based screening, several potential SCI biomarkers were identified in this way. Using a 34-cytokine 204 
sandwich ELISA microarray, Light et al. (2012), identified increased levels of matrix 205 
metalloproteinase-8 protein in CSF samples taken from adult rats at 12 days post-SCI (37), and 206 
Hachisuka et al. (2014) found increased serum levels of the microRNAs miR-9, miR-219 and miR-207 
384-5 in mice at 12hrs after contusion SCI (n=8) compared to sham injury (n=8) using a low-density 208 
microarray platform (Table 1) (38). 209 
 210 
Despite some findings using array technology based screening, as expected, the unbiased quantitative 211 
proteomic comparisons were more fruitful in terms of the numbers of potential biomarkers that were 212 
identified. Using difference gel electrophoresis (DIGE) and mass spectrometry (MS) analysis to 213 
compare CSF from patients at 1-8 days post SCI, Sengupta et al. (2014) identified eight proteins that 214 
were differentially expressed between complete and incomplete injured patients (39) (Table 1). Using 215 
a high-throughput label-free liquid chromatography-MS/MS quantitative proteomics technique, 216 
Lubienicka et al. (2011) compared CSF taken from rats at 24hrs post-SCI and identified 42 putative 217 
biomarkers; 10 of which are indicative of SCI severity (40) (Table 1). Moghieb et al. (2016) also 218 
used MS to identify biomarkers of SCI, however, their approach was not to initially look for CSF or 219 
blood biomarkers, instead they assessed protein changes within spinal cord tissue segments, of which 220 
Transferrin, Triosephosphate Isomerase 1, Cathepsin D and Phosphoprotein Enriched In Astrocytes 221 
15 (PEA-15) were confirmed as altered in human SCI CSF (41).  222 
 223 
Despite proteomics providing a popular platform for novel biomarker identification in many fields of 224 
study, other high-throughput techniques, such as lipidomics and metabolomics are also valuable in 225 
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biomarker identification (36). As is the case with proteomics, only a limited number of published 226 
studies have utilised these approaches to elucidate biomarkers for SCI. Xu et al. (2015) 227 
demonstrated, by assessment of lipidomic analysis of polyunsaturated fatty-acid containing 228 
phosphatidylcholines within the spinal cord tissue, that spatiotemporal expression of one of these 229 
phosphatidylcholines matched with reactive microglia and astrocyte activity (42). Although not 230 
directly relevant to CSF or blood biomarkers, Xu et als’ study indicates that lipidomic analysis of 231 
these fluids may clarify the role of lipid metabolism and damage of the cell membrane following SCI 232 
(42). There is also a need to further study the metabolome of CSF and/or blood of SCI patients, as 233 
this represents the end-point of all gene, transcript and protein interactions (43). Peng et al. (2014) 234 
published a comprehensive paper highlighting that metabolomic analysis of plasma from SCI rats led 235 
to identification of a panel of metabolites that could be used to selectively determine injured 236 
compared to sham injured animals, based on metabolite measurements alone (44). Analysis of these 237 
metabolites within the plasma of human SCI patients’ is required to see if these findings translate to 238 
man and further similar metabolomic studies of human blood samples may also pinpoint other 239 
biomarkers.  240 
 241 
4. Identifying biomarkers in the CSF and blood of pre-clinical models and human SCI patients 242 
using ‘targeted’ approaches 243 
As discussed previously, the vast majority of studies that aimed to assess CSF or blood biomarkers of 244 
SCI have done so based on ‘targeted’ proteins that are known to relate to the biological processes that 245 
occur following a SCI. Many of these biomarkers have so far been assessed in pre-clinical models of 246 
SCI. Pre-clinical models are highly controllable and provide the opportunity to measure differences 247 
in the concentration of a biomarker in animals with a SCI and sham-injured animals (a comparison 248 
not possible using human subjects). These models also allow for longitudinal analyses comparable to 249 
acute, sub-acute and chronic timeframes post-SCI. It is, however, difficult to relate the phases of 250 
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injury in rodent models to that of the human situation, particularly as much depends on which of the 251 
models of injury are used, and as such there is no published consensus of opinion.  252 
 253 
Causes of human SCI are wide-ranging therefore several different animal models have been 254 
generated in an attempt to account for this diversity, although it is extremely unlikely that any animal 255 
model will ever be able to replicate the complexity of human injury. As discussed previously, the two 256 
major categories of SCI are sharp force or “stab” lesions and contusive injuries. In rodent models, 257 
contusion injuries are most commonly induced using blunt force impact devices (45), in which 258 
calibrated weights are dropped onto an impounder which is rested on the surgically exposed spinal 259 
cord (46,47). This technique allows for varying degrees of injury depending on the amount of force 260 
used. Other methods of inducing an injury include the use of an aneurysm clip or calibrated forceps 261 
to compress the cord for a set time-period (48,49). Contusion injuries are commonly used as models 262 
of incomplete injury, whereas to study complete injury, complete transection of the spinal cord is 263 
often carried out using either microscissors or a scalpel blade cutting all of the spinal cord tracts by 264 
surgical incision and under visual control using suction to visually check for a complete injury 265 
(50,51).  266 
 267 
Both human and pre-clinical models have been utilised to identify potential biomarkers of SCI 268 
progression. Tables 2 and 3 detail all of the studies (to our knowledge) that have assessed CSF and/or 269 
blood biomarkers of SCI in pre-clinical and human models, respectively. Here we discuss the leading 270 
candidate biomarkers of SCI severity and prognosis identified thus far, based on their known 271 
relevance to the biological processes that result following SCI.  272 
 273 
4.1 Neurofilament proteins 274 
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Neurofilament proteins (NF) are the most abundant proteins in the neuronal cytoskeleton (52). They 275 
interact with other cytoskeletal proteins to regulate axonal transport and neuronal signalling (52). The 276 
presence of extracellular NF proteins is an indication of axonal damage and NF accumulation is seen 277 
in several neurological diseases (53) including multiple sclerosis (54–56), amyotrophic lateral 278 
sclerosis (54,57) and traumatic brain injury (TBI) (58). NF proteins have long half-lives (3 weeks and 279 
2.5 months for NF-L and pNF-H, respectively) (59,60) and  pNF-H, in particular, is highly resistant 280 
to breakdown by calpain and other systemic proteases (32). These proteins, therefore, provide 281 
attractive candidate biomarkers for SCI as they are not broken down before detection would be 282 
possible. The phosphorylated form of NF-H (pNF-H) (9,34) and NF-L (57,58) are the two subunits 283 
which have been most widely considered as biomarkers for SCI and shall be discussed in more detail 284 
below.  285 
4.1.1 Neurofilament- heavy chain (NF-H) 286 
SCI has been shown to result in increased levels of pNF-H in the CSF and blood of humans, rats and 287 
canines (9,34,61,62), as assessed using ELISA. In rat serum for example, no pNF-H can be detected, 288 
using ELISA, in uninjured and sham injured animals, however, severe experimental SCI results in 289 
high levels of measurable pNF-H (34). A detailed study of serum pNF-H concentrations (again 290 
assessed using ELISA) in rats with contusion (n=8) and spinal hemisection (n=13) injuries resulted in 291 
biphasic pNF-H being detectable in the late acute, sub-acute and chronic phases of both injuries (34). 292 
A sharp peak in pNF-H was observed at 16h post-SCI whilst maximal serum concentrations were 293 
seen at 3 days post-SCI, returning to baseline levels at approximately 18 days (34). 294 
Animal studies have also revealed that blood pNF-H levels can indicate disease severity and directly 295 
relate to functional outcome. Nishida et al. (2012) demonstrated that in dogs with degenerative disc 296 
disease (DDD; n=60), pNF-H levels rose incrementally with the grade of injury severity observed 297 
(62). This study also demonstrated that those animals with the highest serum pNF-H levels at 298 
veterinary presentation post-SCI were not able to regain the ability to walk following surgery (62). 299 
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Ueno et al. (2011) also demonstrated a negative correlation (r -0.78) between rat plasma pNF-H 300 
levels at 3 days post SCI and hindlimb function at 28 days post SCI (assessed using Basso, Beattie, 301 
Breshnahan (BBB) score) (61).  302 
 303 
A small cohort of human studies also indicates that there is a correlation between pNF-H and disease 304 
state. In the CSF of SCI patients (n=15), pNF-H concentrations are higher at 6 to 48h post trauma 305 
compared to that in uninjured individuals (n=6) (35). Further, Pouw et al. (2014), found that NF-H 306 
concentrations in CSF were significantly greater in motor complete (n=9) patients compared to motor 307 
incomplete patients (n=7) (9).  In a recent, slightly larger study, pNF-H levels in the serum of SCI 308 
trauma patients (n=26) were significantly greater compared to controls with spinal fracture but no 309 
spinal cord trauma (n=9) at 24h and 48h post-injury (63). These studies indicate that the 310 
measurement of pNF-H within the CSF and peripheral blood has potential as a prognostic biomarker 311 
in the acute phase of SCI.  312 
 313 
4.1.2 Neurofilament- light chain (NF-L) 314 
Levels of NF-L have been assessed in both the CSF and serum of SCI patients (64,65). Guez et al. 315 
(2003) found there to be increased levels of NF-L in CSF following SCI compared to uninjured and 316 
whiplash injured patients (64). This study also demonstrated that for a patient with complete injury 317 
and complete tetraparesis with no long term neurological improvement, NF-L levels were 10-fold 318 
higher than in a complete injured patient who improved to AIS-D by 15-months post-injury (64). 319 
This indicates that NF-L also may have utility as a biomarker of a patients’ prognosis. In the later, 320 
larger study, NF-L correlation with SCI severity and neurological outcome was confirmed (65). NF-321 
L concentrations were found to be higher in the motor complete (n=13) patients (70 pg/mL) and 322 
motor incomplete (n=10) patients compared to others with central cord syndrome (n=4; 6 pg/mL) and 323 
uninjured controls (n=67; 5pg/mL).  Unlike pNF-H, the potential of NF-L as a biomarker for SCI has 324 
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not been strengthened by pre-clinical studies. Despite this, NF-L is shown in preliminary human 325 
studies to have potential value in the classification of patients with or without capacity for 326 
neurological improvement. 327 
 328 
4.2 Tau 329 
Tau proteins are microtubule stabilising proteins that are highly abundant in neurons (66–68). Like 330 
NFs, these proteins function to maintain axonal transport and neuronal transmission (69). Expression 331 
of Tau proteins within the CSF or blood of animals and humans is likely indicative of neuronal 332 
damage, as these proteins are not usually secreted (10). Although several investigations into the use 333 
of Tau as a biomarker for neurodegenerative diseases, such as conversion from mild cognitive 334 
impairment to Alzheimer’s disease (70), have been described, there are fewer studies examining 335 
these proteins as putative biomarkers for SCI.  336 
 337 
There are no publications of SCI research into Tau as a biomarker in typical laboratory animal model 338 
of SCI, however, veterinary studies looking to use Tau as a marker of SCI in dogs following IVD 339 
herniation (IVDH) suggest that an acute rise in Tau levels might indicate decreased capacity for 340 
functional recovery (71). In a study of 51 dogs, CSF was collected immediately upon admission to 341 
the veterinary hospital (71). As well as Tau levels increasing with injury severity (higher in 342 
incomplete injured compared to healthy animals and in complete compared to incomplete injured 343 
animals), the highest levels of CSF Tau protein corresponded with those dogs which took the longest 344 
time to recover function (71).  345 
 346 
In human studies, the consequence of SCI on Tau levels is not overly clear. Pouw et al. (2014) 347 
assessed Tau levels in CSF collected between 3-24h post-injury in motor complete and motor 348 
incomplete patients (with 7/16 patients having their CSF drawn before 15 hours post-injury) and 349 
 15
found no significant differences associated with the degree of SCI (9). In contrast, two studies from 350 
Kwon et al. (2010 & 2016) found that in CSF collected from complete or incomplete patients 24h 351 
post-injury, Tau concentrations were significantly elevated in a severity-dependent manner (72,73). 352 
This discrepancy between the studies could be due to a difference in patient numbers (Pouw et al. 353 
(2014), n=16; Kwon et al. (2010), n=27; Kwon et al. (2016), n=50) and possibly a difference in time 354 
between injury and CSF analysis (9,72,73). In combination with other markers, Tau can predict 355 
initial AIS grade and if its’ baseline measurement is low it can predict an improvement in AIS grade 356 
by 6 months post-injury (73). 357 
  358 
Kwon et al. (2010) plotted Tau concentrations within the CSF from 8 to 120 hours following a SCI 359 
(72). Interestingly, the concentration of Tau remained higher in AIS-A patients compared to AIS-B 360 
and AIS-C graded patients through to 48h after injury however no difference in CSF concentrations 361 
of Tau existed between 48 and 120h post-injury (72). This observation highlights the dynamic nature 362 
of the biological processes that follow a SCI and the importance of assessing candidate biomarkers 363 
over time to ensure the most appropriate time is selected for measurement of differences in 364 
biomarkers.  365 
 366 
4.3 Neuron Specific Enolase (NSE) 367 
Neuron specific enolase (NSE) is the dimeric neuronal form of the glycolytic enzyme enolase. This 368 
enzyme is a marker of ischemic brain damage (74) and although it only has a short biologic half-life 369 
(≤ 24h) (75), NSE holds promise as an acute indicator of neuronal damage. 370 
 371 
NSE levels are elevated in the CSF, plasma (76) and serum (77) of rats in the acute phase of SCI. 372 
Further, NSE levels continue to be elevated at 24h post-injury in the serum of SCI compared to sham 373 
injured rats (77), however, assessment in CSF or plasma for time-periods greater than 24h post-SCI 374 
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has not been evaluated in rodent models. Again, in humans NSE has only been assessed in the acute 375 
period post-injury (≤24h) (9,78) and measurement outside of this timeframe may be inappropriate 376 
with respect to the short half-life of this protein.  377 
 378 
Nonetheless, NSE has been shown to have potential as an indicator of SCI severity. In rats with mild 379 
(n=20), moderate (n=20) and severe (n=20) spinal cord contusion injuries, 6h measurements of CSF 380 
and plasma showed significantly greater levels of NSE in moderately and severely injured rats (with 381 
greater NSE levels in the severely vs. moderately injured) compared to mildly injured animals (77). 382 
In humans, higher NSE concentrations were observed in the CSF of motor complete (n=9) compared 383 
to motor incomplete patients (n=7)(9). Results from Wolf et al. (2014) however, suggest that 384 
measurement of NSE in the serum of patients may be inappropriate to assess disease severity, as 385 
serum NSE concentrations within 24h of injury were no different when compared to vertebral injured 386 
patients with (n=12) or without (n=22) neurological deficit (78). 387 
 388 
4.4 S100 calcium binding protein β (S100β) 389 
S100β is a glial specific S100 protein that is released into blood and CSF during the acute phase of 390 
brain injury (79). S100β is involved in a diverse range of functions including calcium homeostasis, 391 
enzyme activity and metabolism, cell proliferation and differentiation (80). Measurement of S100β 392 
has potential as an acute marker of SCI, as it is significantly increased in the blood (76,77,81) and 393 
CSF (76) of rats at 6h after severe contusion injury compared to sham injury. In the human acute 394 
setting (<48h), S100β is also increased in the serum of patients with vertebral spine fractures 395 
(mean=0.77 μg/L; n=34) compared to uninjured patients (0.14 μg/L; n=29) (78) and in the CSF of 396 
AIS-A grade patients compared to those with an AIS-B or C ISNCSCI score (73). Further, Pouw et 397 
al. (2014) showed there to be higher levels of detectable S100β in the CSF at 24h in those patients 398 
who did not show improvement in AIS score at 6 or 12 months post-injury (9). This finding is 399 
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corroborated by Kwon et al. (2016), who showed decreased S100β concentrations within the CSF up 400 
to 48h after injury in SCI patients who demonstrated an improvement in AIS grade by 6 months post-401 
injury (73). Therefore, early acute phase assessment of S100β within the CSF could provide a 402 
predictive biomarker of neurological improvement.  403 
 404 
 Assessment of serum and CSF S100β concentrations outside of the acute setting has not yet been 405 
studied. However, results from animal studies demonstrate that by 24h post-injury, S100β levels are 406 
unaltered in response to SCI (77), perhaps limiting the potential of this biomarker for clinical use to 407 
the acute setting only. In addition, S100β has been measured in conjunction with NSE in two animal 408 
studies (76,77) which indicated that co-measurement, rather than singular measurement of these 409 
markers in the acute stages of injury is a more robust prognostic indicator of SCI severity. 410 
 411 
4.5 Glial Fibrillary Acidic Protein (GFAP) 412 
The intermediate filament protein found in astroglia, glial fibrillary acidic protein (GFAP), is a 413 
widely acknowledged biomarker of severe brain damage resulting from haemorrhage or serious 414 
trauma, with both serum and CSF levels being higher in patients with traumatic brain injury (TBI) 415 
compared to uninjured controls (82). Despite the fact that GFAP is an established marker of neural 416 
injury in other fields, very few studies have investigated its potential as a biomarker of SCI.  In a 417 
small preliminary study, Yokobori et al. (2015), demonstrated higher GFAP levels in the CSF of rats 418 
in the acute phase following contusion injury (n=4) compared to sham injured animals (n=4) (83). 419 
Ahadi et al. (2015) (63) demonstrated that GFAP is also increased in the serum of human acute SCI 420 
patients (n=26) compared to uninjured controls (n=9). Further, Pouw et al. (2014) and Kwon et al. 421 
(2016) confirmed that CSF GFAP concentrations were higher in complete vs. incomplete SCI 422 
patients and hence that GFAP concentrations appear to be associated with SCI severity (9,73). 423 
Measurement of CSF GFAP within 48h of injury has also been used, in combination with other 424 
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inflammatory and structural markers, to predict which AIS-A patients would show an improvement 425 
in AIS score by 6 months post-injury, with an 83% success rate (73). Therefore acute assessment of 426 
CSF GFAP may provide a predictive biomarker of neurological improvement.  Longitudinal analyses 427 
by Yokobori et al (2015) (83) showed maximal GFAP levels in CSF in rats at 4h post SCI, with CSF 428 
concentrations decreasing sequentially at 24h and 48h after injury (83); further studies are required to 429 
ascertain GFAP levels in the chronic phase of SCI.  430 
4.6 Pro-inflammatory cytokines 431 
Unsurprisingly, SCI can lead to the release of pro-inflammatory cytokines across the BBB. 432 
Therefore, several researchers have investigated whether concentrations of these cytokines in the 433 
blood of SCI patients relate to neurological outcome. TNF-α is a cytokine involved in the acute phase 434 
of pro-inflammatory signalling and is increased in the serum of SCI patients (n=56) compared to 435 
uninjured controls (n=35) in the sub-acute phase (2-52 weeks) (84). This pattern of increased serum 436 
TNF-α concentrations following SCI (n=6) compared to sham injury is maintained in rats (85). 437 
Moreover, SCI patients who show improved neurological function, had lower TNF-α at 9h, 438 
compared to SCI patients who failed to improve neurologically (16). Interleukin 1 beta (IL-1β) is a 439 
key moderator of proliferation and inflammation that is thought to be vital for the formation of the 440 
glial scar (86). Ischaemia/ reperfusion SCI in rats (n=6) resulted in increased serum IL-1β levels at 441 
both 24 and 48 hrs after injury when compared to sham injured rats (n=6) (85). Despite human CSF 442 
or blood measurements of IL-1β not having been compared between SCI and uninjured individuals, 443 
baseline assessment (4 hrs after hospital admission) of this cytokine in serum showed no difference 444 
between patients who did or did not show an improvement in AIS score (16). Between weeks 1 and 4 445 
after injury, however, serum IL-1β concentrations decreased significantly, only in patients who did 446 
not show an improvement in AIS score (16), indicating that maintenance of higher serum IL-1β 447 
concentrations may lead to improved neurological outcome. Previously, a pre-clinical model has also 448 
indicated that Interleukin 6 (IL-6) may be a suitable blood biomarker to diagnose SCI, as at both 24 449 
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and 48 hrs after SCI serum concentrations of IL-6 were greater when compared to sham injured 450 
rodents (85). More recently, Kwon et al (2016) have demonstrated CSF concentrations of pro-451 
inflammatory cytokines IL-6 and Interleukin 8 (IL-8) can be assessed in the acute phase of human 452 
injury (≤48h) to both determine injury severity and to predict neurological improvement from an 453 
AIS-A to either AIS-B or C grade by 6 months post-injury (73). 454 
 455 
4.7 Soluble CD95 ligand (sCD95L) 456 
During the acute and subacute phase of SCI, neuronal damage via apoptosis is prolific. The Fas 457 
ligand receptor system is key in driving this apoptotic response (87). Soluble CD95 ligand 458 
(sCD95L/Fas-L) is a cleavage product of the type II transmembrane protein CD95L (17), which 459 
when activated and bound to CD95 (Fas) can initiate the Fas apoptotic pathway. sCD95L induces 460 
neutrophil secretion of pro-inflammatory chemokines (88). Although blocking the CD95 pathway in 461 
SCI rats improved functional outcome, assessment of human blood sCD95L via ELISA, showed no 462 
difference in concentration when comparing complete vs. incomplete injured patients at 4h and 12 463 
weeks post injury (89,90). It is of note, however, that in these human studies no uninjured control 464 
group was included; as such it is difficult to determine whether sCD95L concentration alters at all in 465 
response to SCI. 466 
 467 
5. Discussion 468 
This review has aimed to evaluate biomarkers in the CSF and/or blood that are currently under 469 
assessment as potential indicators of SCI diagnosis, severity and likely neurological outcome in 470 
preclinical and clinical studies. These studies have aimed to establish whether biomarker detection in 471 
CSF and blood is possible, to determine the longevity and stability of these biomarkers in each body 472 
fluid, and their value in predicting neurological outcome, as assessed by ISNCSCI score. All of the 473 
studies described are either in the pre-clinical stages of biomarker validation or have been undertaken 474 
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only in a small number of human patients. Pre-clinical models provide an invaluable tool in which 475 
biomarker characteristics can be studied without the added complexity of clinical human-to-human 476 
SCI variability. Importantly, the use of sham-injured animals for comparison ensures that biomarkers 477 
that are specific to SCI are identified, as sham-injury can account for systemic responses, such as 478 
systemic inflammation, that may occur in relation to the ‘trauma’ of sham injury. In human studies 479 
that have compared biomarkers between SCI and healthy ‘controls’ (91), such healthy individuals are 480 
unlikely to demonstrate any of the systemic biological responses that may exist, therefore some of 481 
the protein differences observed between the injured and control groups are likely to be non-specific 482 
to SCI. Access to appropriate human ‘sham injury controls’, where the same level and type of trauma 483 
is observed along with matched patient demographics but without any injury to the spinal cord tissue 484 
is impossible to obtain. Guez et al. (2003), however, have assessed the utility of comparing SCI 485 
patients to individuals who had severe whiplash as a form of human ‘sham’ injured control. The 486 
majority of candidate biomarkers in the described literature represent neural structural proteins which 487 
are likely to be damaged following SCI and released into the CSF and blood following disruption of 488 
the BBB. A cautionary aspect to consider for these SCI biomarkers is that some are known to 489 
increase in the CSF and blood of individuals with brain injury or nervous system disease 490 
(58,74,79,82); these confounding factors should be taken into consideration when exploring their 491 
utility in the clinic, especially in incidences of polytrauma. Further, some of the biomarkers that have 492 
indicated potential in SCI biomarker development have a short half-life (e.g. NSE), therefore 493 
accurate measurement of these may need to be carried out immediately after injury. Unfortunately, 494 
the assessment of SCI biomarkers in the acute setting (<24h) might not always be possible, 495 
particularly in complex polytrauma cases where patient stabilisation is the priority. 496 
 497 
Several of the studies included in this review have assessed biomarkers solely within the CSF. It is 498 
intuitive to think that body fluids local to the injury site will contain the highest concentration of SCI 499 
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specific molecules, metabolites or proteins. This has been confirmed by studies that have directly 500 
compared human biomarker concentrations in matched CSF and blood samples, which have 501 
demonstrated that acutely after injury (≤48h) concentrations of IL-6, IL-8, MCP-1, Tau, S100β and 502 
GFAP were at least 10 fold higher in the CSF compared to the blood (72); much higher CSF 503 
concentrations of biomarkers, including GFAP, were also demonstrated by Yokobori et al. (2015) 504 
(83). The collection of CSF from SCI patients however, increases their risk of infection of the 505 
meninges and has cost implications for the health service provider (92). Alternatively, if biomarkers 506 
can be identified systemically, the collection and analysis of peripheral blood would represent a less 507 
risky and more cost-effective approach. Therefore, there is benefit in pursuing techniques that are 508 
sensitive enough to detect differences in biomarker concentrations in blood, however, initial 509 
assessment of potential biomarkers may best be carried out in CSF where more apparent changes are 510 
likely to be noted. 511 
 512 
The majority of published studies that have assessed blood or CSF biomarkers in human SCI patients 513 
have assessed the effectiveness of a biomarker based on its ability to predict or correspond to 514 
ISNCSCI score. However, it may be that other measures of progression, such as improvements in 515 
hand grasping, medical imaging or electrophysiology provide more subtle improvements, which 516 
could more easily be unpicked by a difference in biomarkers. 517 
 518 
The use of unbiased approaches to screen for putative biomarkers of SCI progression in CSF and 519 
blood, for example quantitative proteomic approaches, have so far been largely overlooked, but are 520 
likely to yield the greatest number of novel biomarker targets. The limited proteomic analyses of 521 
CSF from SCI patients that exists provides a benchmark for the number of novel candidates that can 522 
be identified (41), however, there is currently a lack of any essential follow-on validation via 523 
quantitative western blot or ELISA. An alternative approach to identifying novel biomarkers using a 524 
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high-throughput approach, may be to assess protein changes within the spinal cord tissue and then 525 
evaluate whether these changes are reflected in the CSF or bloods, as could be demonstrated by 526 
Moghieb et al. (2016) (41). Alternatively, as bioinformatic approaches aimed at interpreting large 527 
proteomic datasets improve, initial in silico validation of the candidate biomarkers might be possible 528 
as an interim step before completing costly quantitative validation; an approach which has been 529 
effective in Alzheimer’s disease (93). 530 
 531 
In this review, we have evaluated the current state-of-play in the CSF and/or blood biomarkers of 532 
SCI research landscape, this review highlights some of the potential pitfalls which need to be 533 
overcome to ensure the clinical utility of biomarker candidates, such as accounting for polytrauma 534 
and delayed SCI diagnoses. In addition, it is clear that further investigation is required, to include 535 
much larger cohorts of human participants with a diverse range of injuries in order to confirm the 536 
clinical validity of the preliminary biomarker findings described. The need to identify and validate 537 
novel prognostic biomarkers that can be measured within the blood or CSF, for the assessment of 538 
SCI progression using unbiased approaches has also been discussed. 539 
 540 
It is highly unlikely that a single biomarker measurement will ever be used on its own to accurately 541 
predict SCI recovery in the clinic. We suggest that demographic and injury associated risk factors as 542 
well as the evaluation of ‘dry’ biomarkers i.e. radiological imaging modalities and 543 
electrophysiological measurements in combination with the quantitation of several validated CSF 544 
and/or blood biomarkers will ultimately be used to provide a ‘risk of SCI progression’ index. Such a 545 
prognostic risk index would greatly advance the clinical management of SCI patients, reducing 546 
uncertainty for both patients and health care providers in the acute SCI setting and providing 547 
confidence in neurological stability prior to the recruitment of SCI patients into clinical trials. 548 
 549 
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Finally, this review highlights the fact that very few studies have been published to identify 550 
biomarkers for other uses in the SCI field. Undoubtedly, biomarkers that could be used in clinical 551 
trials that aim to target specific disease mechanisms, such as remyelination, would be invaluable for 552 
assessing efficacy of a particular treatment and the mechanism of interest. Further, biomarkers that 553 
could be used to identify patients who will develop other long-term problems, such as neuropathic 554 
pain would also be advantageous for the stratification of patients to particular treatment.555 
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Reference Injury Type Sample 
numbers 
Species Sample Time of 
sampling 
(after SCI) 
Method of Biomarker 
screening 
Candidate Biomarkers 
Light et al., 
2012 (37) 
Contusion 
Sham 
n=4 
n=4 
Rat CSF 12 days Cytokine ELISA microarray Matrix Metalloprotease-8 
Thymus Chemokine-1 
Hachisuka et 
al., 2014 (38) 
Contusion (mild) 
Contusion (severe) 
Sham  
Untreated 
n=8 
n=8 
n=8 
n=8 
Mouse Serum 12h Taq-man low density array miR-219 
miR-384-5p 
miR-9 
Sengupta et al., 
2014 (39) 
 
Complete 
Incomplete 
 
 
Complete 
Incomplete 
n=7 
n=8 
 
 
n=3 
n=3 
Human CSF 1-8 days (acute) 
 
 
15-60 days 
(sub-acute) 
Difference gel electrophoresis 
(DIGE) and matrix assisted 
laser desorption/ ionisation- 
mass spectrometry (MALDI-
MS) 
GTF3C5 
HP 
IGHG2 
IGHG4 
ALB 
TF 
AZGP1 
APOH 
Lubienicka et 
al., 2011 (40) 
Contusion (moderate) 
Contusion (severe) 
Sham 
n= 9 
 
n= 9 
n= 9 
Rat CSF 24h Liquid chromatography-mass 
spectrometry (LC-MS/MS) 
YWHAG 
ORM1 
A1M 
A2M 
APOA1 
APOH 
B2M 
CA1 
CA2 
C3 
C1 
CRP 
FAM3C 
GPX3 
ITIH4 
ITIH3 
LASMP 
F11R 
KNG1 
LDHA 
IGKC 
NBL1 
SCG5 
PRDX2 
PZP 
ZMYND8 
S100A8 
F2 
SCG3 
SERPINC1 
CDH13 
MAP1 
YWHAZ  
 
Table 1 Candidate blood and/or CSF biomarkers for SCI identified from high-throughput techniques 
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Reference Biomarker Injury type Sample  
numbers 
Species Sample  Time of 
sampling 
 (after 
SCI) 
Findings 
Ueno et al., 
2011 (61) 
pNF-H Moderate 
contusion 
n=4 Rat Plasma 1, 2, 3, 4 
days 
Investigated if minocycline treatment could improve recovery
following SCI by looking at pNF-H as a potential biomarker.  
pNF-H was detectable from 1 day post SCI, with levels peaking at 3
days.   
pNF-H levels were lower in rats which had improved hindlimb
function (BBB score).  
A negative correlation between pNF-H level at 3 days post SCI and
BBB score at 28 days post injury existed. 
Nishida et al., 
2012 (62) 
NF-H Paraplegia with 
IVDH 
n=60 
control: n=6 
Dog Serum 1-3 days pNF-H was higher in animals with worse paraplegia (grade 5 vs
grade 4).  
Eight dogs with the highest pNF-H levels were unable to walk
following surgery. 
Shaw et al., 
2005 (34) 
pNF-H Contusion 
Spinal 
hemisection 
n=8 
n=13 
Rat Serum 5, 2, 8, 16, 
24h 
2-21 days 
Increased pNF-H in SCI (contusion and spinal hemisection) injured
vs. sham injured.  
pNF-H increased in the first few hours of injury and peaked at 16h
post SCI.  
pNF-H levels had a second high peak observed at 3 day post SCI
before returning to baseline levels at 18 days post SCI. 
Roerig et al., 
2013 (71) 
Tau IVDH n=51 Dog CSF At time of 
veterinary 
admission 
Tau levels were increased in dogs with motor complete injury
compared to healthy or motor incomplete injured dogs.  
Dogs which improved at least one neurological grade within a week
had lower tau concentrations than those that took longer to recover. 
Loy et al., 
2005 (77) 
NSE; S 00β Moderate 
contusion 
Severe contusion 
n=12 
n=10 
Rat Serum 6, 24h Significantly higher serum NSE levels were noted at 6h and 24h
following SCI compared to sham injured animals.  
Significantly higher serum S100β levels at 6h in severely injured
rats.  
S100β levels were not significantly different wh n comparing SC
and sham injured rats at 24h. 
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Cao et al., 
2008 (76) 
NSE; S100β Mild contusion 
Moderate 
contusion 
Severe contusion 
n=20 
n=20 
n=20 
Rat CSF; S ru
m 
30 mins 
2,6,12,24h 
Significant increase in NSE and S100β levels in both serum and
CSF from 2h post SCI compared to sham injury.  
At 6h post SCI, CSF and plasma NSE and S100β were significantly
higher in moderate and severely injured rats compared to m ldly
injured rats and were significantly higher in severely injured rat
compared to moderatel  injured rats. 
Ma et al., 2001 
(81) 
S100 Spinal 
compression 
n=40 
control: 
n=24 
Rat Serum 2, 6, 13, 
24h 
3, 6, 10 
days 
Serum S100 increased within 3h after injury in the SCI rats. 
Levels of serum S100 peaked at 3h, 12h and 3 days after SCI and
was significantly higher than levels in serum of sham injured rats a
all three time points tested. 
Yokobori et 
al., 2015 (83) 
GFAP; 
SBDP120; 
SPDP145 
Contusion n=4 Rat CSF 4, 24, 48h GFAP and UCH-L1 levels in the CSF were increased at 4h, 24h
and 48h post SCI compared to sham injury.  
CSF GFAP levels were highest at 4h post injury, then decreased a
24h and 48h.  
UCH-L1 was increased at 4h but not 24h or 48h after SCI when
compared to sham injured animals. 
Hasturk et al., 
2009 (85) 
TNF-α 
IL-1β 
IL-6 
Spinal ischemia/ 
reperfusion 
n=6 Rat Serum 24, 48h Serum TNF-α, IL-1β and IL-6 was elevated following ischemia
reperfusion injury compared to sham injury at 24 and 48 hrs. 
None of the cytokines showed altered abundance at 24 compared to
4  hr  in injured rats.  
Hachisuka et 
al., 2014 (38) 
miRNA Mild contusion 
Moderate 
contusion 
n=8 
n=8 
Mice Serum 3, 12, 24h 
3, 5, 7, 14, 
21, 28, 35, 
42 days 
miR9 and miR384-5p were significantly higher in mouse serum a
3h, 12h, 24h and 72h following SCI compared to sham injured mice
miR219 was significantly higher in mouse serum at 3h, 12h and 24h
following SCI compared to sham injury. 
 
 
 
 
Table 2 Biomarkers of SCI identified and/or validated using animal models 557 
Abbreviations: BBB, Basso, Beattie, Breshnahan score; CSF, cerebrospinal fluid, IVDH, intervertebral disc herniation; NF-H, neurofilament heavy chain; NSE, 558 
neuron specific enolase; GFAP, glial fibrillary acidic protein; S100β, S100 calcium binding protein β; SCI, spinal cord injury 559 
 560 
 561 
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 562 
 563 
 564 
Reference Biomarker Patient groups Sample  
numbers 
Spinal Level 
(n) 
AIS 
Grade (n) 
Age [y] 
Mean 
(Range) 
M/F ratio 
Sample/ 
Assay 
Type 
Time of 
sampling 
(post-injury) 
Findings 
Ahadi et al., 
2015 (63) 
GFAP;  
pNF-H; 
NSE 
Traumatic SCI 
 
 
 
Control (Spinal 
fracture, no 
trauma) 
n=26 
 
 
 
n=9 
C (8) 
T (8) 
L (10) 
A (10) 
B (7) 
C&D (9) 
All (n=35) 
37  
(16-64) 
30/5 
Serum/ 
ELISA 
 
 
 
24h; 
48h;  
72h 
GFAP sig. 
increased in 
trauma SCI vs 
controls at all 
time points. 
GFAP related to 
SCI severity. 
pNF-H & NSE 
sig. increased in 
trauma SCI vs 
controls at 24 & 
48h after injury. 
Biglari et al., 
2013 (89) 
sCD95L Traumatic SCI n=8 C (5) 
T (3) 
A (2) 
B (1) 
C (3) 
D (2) 
48  
(18-86) 
5/3 
Serum/ 
Immuno-assay 
24h; 
At day 3, 7, 14, 
28 & 90 
No difference 
detected between 
patients, but 
levels decreased 
during the 1st 
week, increased 
during the 2nd 
week, were 
highest in the 4th 
week and levels 
plateaued at 12 
weeks.  
Biglari et al., 
2015a (90) 
sCD95L Traumatic SCI n=23 C (8) 
T (9) 
L (6) 
A (15) 
B (6) 
C (2) 
43  
(18-85) 
16/7 
Serum/ 
Immuno-assay 
On admittance; 
4, 9, 12 & 24h;  
3 & 7 days; 
2, 4, 8 & 12 
weeks post-
admission 
sCD95L was 
significantly 
reduced during 
the first 24h, but 
was significantly 
higher c.f. 
admission levels 
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at 8 weeks. 
Biglari et al, 
2015b (16) 
IL-1β; 
TNF-α 
Traumatic SCI n=23 C (8) 
T (9) 
L (6) 
A (15) 
B (6) 
C (2) 
43  
(18-85) 
16/7 
Serum/ 
Immuno-assay 
On admittance; 
4, 9, 12 & 24h;  
3 & 7 days; 
2, 4, 8 & 12 
weeks post-
admission 
Improvers were 
found to have 
lower TNF-α at 
9h c.f. non-
improvers. 
IL-1β declined in 
all patients 
between 2 & 12 
weeks. 
Davies et al., 
2007 (84) 
IL-1β, IL-6, 
TNF-α, IL-4, 
IL-10, IL-2, IL-
1RA, myelin-
associated 
glycoprotein, 
GM1 
ganglioside IgG 
(G & M) 
Traumatic SCI 
 
 
 
 
Control 
n=56 
 
 
 
 
n=35 
Between 
C4 & T12 
A (14) 
B (13) 
C (22) 
D (7) 
41 
42/14 
 
 
 
35  
(18-65) 
18/17 
Serum/ 
ELISA 
1st visit at rehab 
22 (2-52 wk 
post-injury) 
34 (>52 wk) 
Excluded patients 
with 
communicable 
diseases, cancer 
diagnosis or on 
anti-inflammatory 
medication also 
with nontraumatic 
aetiologies such 
as epidural 
abscess, 
aneurysm etc. 
IL-6, TNF-α, IL-
1RA & anti-GM 
was increased in 
SCI patients c.f. 
controls. 
These levels are 
increased further 
in SCI patients 
presenting with 
neuropathic pain, 
UTIs & pressure 
ulcers. 
Guez et al., 
2003 (64) 
GFAP; 
NF-L 
Cervical 
fracture 
dislocation with 
neurological 
deficit 
Severe whiplash 
with 
neurological 
deficit 
Control (no 
n=6 
 
 
n=17 
 
 
n=24 
C (6) A (3) 
B (1) 
D (2) 
48  
(40-69) 
5/1 
39  
(26-56) 
11/6 
31  
(23-56) 
12/12 
CSF/ 
ELISA 
1-21 days Exclusions 
included patients 
with head injury 
or 
unconsciousness. 
GFAP & NF-L 
increased in 
cervical fracture 
dislocation group. 
NF-L was 
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neurology) increased in 3 
patients with 
whiplash 
indicating axonal 
injury. 
Kuhle et al., 
2015 (65) 
NF-L Motor-complete 
SCI 
CCS 
 
Motor-
incomplete SCI 
Healthy controls 
(no neurological 
Deficit) 
n=13 
 
n=4 
 
n=10 
 
n=67 
C (11) 
T (2) 
C (4) 
 
C (9) 
T (1) 
 
A (12) & B (1) 
 
C (2) & D (2) 
 
C (7) & D (3) 
32  
(22-45) 
8/5 
49  
(39-62) 
3/1 
33  
(22-43) 
7/3 
35  
(28-42) 
29/38 
Serum/ 
In-house 
immuno-assay 
12h & 
every 12h 
subsequently up 
to 7days 
NF-L correlated 
with severity & 
neurological 
outcome. 
Kwon et al., 
2010 (72) 
25-plex 
cytokine array 
plus IL-16 & 
growth factors; 
Tau;  
S100β; 
GFAP 
Complete SCI 
 
Incomplete SCI 
 
Controls 
(undergoing 
operations for 
hip, knee or 
spine) 
n =14 
 
n=13 
 
n=12 
C (11) 
T (3) 
C (10) 
T (3) 
A (14) 
 
B (7) & C (6) 
All (n=27) 
48  
(20-66) 
19/8 
CSF & Serum/ 
ELISA & 
Multiplex array 
system 
≤72h 
 
Exclusions – 
concomitant head 
injuries, major 
trauma to chest, 
pelvis or 
extremities 
requiring 
intervention or if 
too sedated or 
intoxicated to 
assess neurology. 
Produced a 
biochemical 
model using a 
combination of 
S100β, GFAP & 
IL-8 from CSF to 
reliably (89% of 
patients) predict 
injury severity 
(AIS- A, B or C) 
at 24h post-injury. 
These markers 
also predicted 
segmental motor 
recovery at 6 
months. 
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Kwon et al., 
(2016) (73) 
Tau, 
S100β 
GFAP 
IL-6 
IL-8 
MCP-1 
Traumatic SCI  n=50 C (32) 
L (3) 
T (15) 
A (29) 
B (12) 
C (9) 
41.9 
4/1 
CSF/ ELISA ≤48h GFAP, IL-6, 
S100β and Tau 
were significantly 
different between 
AIS- A, B and C 
grade individuals. 
A discriminant 
function analysis 
model showed 
83% success rate 
at predicting 
baseline AIS 
grade based on 
CSF 
concentrations of 
all of these 
biomarkers  
together. Baseline 
concentrations of 
IL-6, IL-8 MCP-
1, Tau, S100β and 
GFAP were 
different between 
those who 
showed 
neurological 
improvement 
(conversion of 
AIS grade 6 
months) 
compared to those 
with the same 
AIS grade at 6 
months. 
 
Pouw et al., 
2014 (9) 
GFAP; 
NSE;  
S100β;  
Tau;  
NFH 
Motor-complete 
SCI 
Motor-
incomplete SCI 
 
n=9 
 
n=7 
C (6) 
T (3) 
C (5) 
T (2) 
A (7) 
B (2) 
C (4) 
D (3) 
All (n=16) 
46  
(18-84) 
10/6 
CSF/ 
ELISA 
≤24h Patients requiring 
interventions for 
major trauma to 
chest, pelvis 
and/or extremities 
or with pre-
existent 
neurodegenerative 
disorders were 
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excluded. 
NSE, S-100β & 
NFH were 
increased in 
motor-complete 
c.f. motor-
incomplete 
patients. 
Ungureanu et 
al., 2014 (35) 
pNF-H Complete SCI 
 
Incomplete SCI 
 
Normals 
n=8 
 
n=7 
 
n=6 
C (6) 
T (2) 
C (4) 
T (3) 
A (8) 
 
B,C, D (7) 
 
E (6) 
35  
(21-53) 
6/2 
45  
(33-59) 
5/2 
CSF/ 
ELISA 
6-12h, then 
daily until 
discharge or 
death 
Patients 
presenting with 
TBI & chronic 
CNS pathologies 
were excluded.  
pNF-H was 
detectable in all 
SCI patients, but 
was more 
elevated in 
complete SCI. 
 
Wolf et al., 2014 
(11) 
NSE; 
S100β 
Vertebral spine 
fractures with 
neurology 
deficit 
Vertebral spine 
fractures with 
no neurology 
deficit 
Control (acute 
fractured femur) 
n=12 
 
 
n=22 
 
 
n=29 
 Complete (5) 
Incomplete 
(6) 
Parasthesia 
(1) 
Spinal fracture 
(n=34) 
53  
(16-94) 
20/14 
77  
(22-94) 
8/21 
Serum/ 
Immuno-assay 
≤ 24h Patients excluded 
were those with 
TBI, requiring 
intubation or 
unstable, open 
fractures, 
pregnancy, 
polytrauma or 
severe penetrating 
injuries. 
S100β was 
increased in 
patients with 
vertebral fractures 
and was 
significantly 
highest in patients 
with neurology 
deficit. 
Yokobori et al, 
2015 (83) 
UCH-L1; 
SBDPs; 
MBP; 
GFAP 
 
Moderate-
severe SCI 
Non-SCI (with 
hydrocephalus 
or unruptured 
n=7 
 
n=15 
 A, B & C (7)  CSF & serum/ 
ELISA 
≤ 24h Preliminary data 
suggesting that 
the structural 
proteins UCH-L1 
& SBDPs may be 
 32
aneurysm) biomarker 
candidates for 
SCI . 
 565 
Table 3 Biomarkers used in traumatic human SCI  566 
Abbreviations: CSF, cerebrospinal fluid; NF-H, neurofilament heavy chain; NSE, neuron specific enolase; GFAP, glial fibrillary acidic protein; S100β, S100 567 
calcium binding protein β; SCI, spinal cord injury; TBI, traumatic brain injury.568 
 33
References 
 
1.  Medicine Consortium for Spinal Cord. Early acute management in adults with spinal cord injury: a 
clinical practice guideline for health-care providers. J Spinal Cord Med. 2008;31(4):404–79.  
2.  Masri E. Management of Traumatic Spinal Cord Injuries: current standard of care revisited. Adv Clin 
Neurosci Rehabil. 2010;10(1):37–40.  
3.  Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, Kalichman M, Rask C, et al. Guidelines for 
the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial 
inclusion/exclusion criteria and ethics. Spinal Cord. 2007;45(3):222–31.  
4.  Fehlings MG, Vaccaro A, Wilson JR, Singh A, Cadotte DW, Harrop JS, et al. Early versus delayed 
decompression for traumatic cervical spinal cord injury: Results of the surgical timing in acute spinal 
cord injury study (STASCIS). PLoS One. 2012;7(2).  
5.  Fawcett JW, Curt A, Steeves JD, Coleman WP, Tusynski MH, Lammertse D, et al. Guidelines for the 
conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery 
after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord. 
2007;45(3):190–205.  
6.  El Masri WS, Kumar N. Traumatic spinal cord injuries. Lancet. 2011;377(9770):972–4.  
7.  Bunge RP, Puckett WR, Becerra JL, Marcillo A, Quencer RM. Observations on the pathology of 
human spinal cord injury. A review and classification of 22 new cases with details from a case of 
chronic cord compression with extensive focal demyelination. Adv Neurol. 1993;59:75–89.  
8.  Bunge RP, Puckett WR, Hiester ED. Observations on the pathology of several types of human spinal 
cord injury, with emphasis on the astrocyte response to penetrating injuries. Adv Neurol. 
1997;72:305–15.  
9.  Pouw MH, Kwon BK, Verbeek MM, Vos PE, van KA, Fisher CG, et al. Structural biomarkers in the 
cerebrospinal fluid within 24h after a traumatic spinal cord injury: a descriptive analysis of 16 
subjects. Spinal Cord. 2014;52(6):428–33.  
10.  Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, et al. Tau in cerebrospinal fluids: 
establishment of the sandwich ELISA with antibody specific to the repeat sequence of tau. Neurosci 
 34
Lett. 1995;186(2-3):181–3.  
11.  Wolf H, Krall C, Pajenda G, Leitgeb J, Bukaty AJ, Hajdu S, et al. Alterations of the biomarker S-
100B and NSE in patients with acute vertebral spine fractures. Spine J. 2014;14(1):2918–22.  
12.  Zetterberg H, Smith DH, Blennow K. Biomarkers of mild traumatic brain injury in cerebrospinal fluid 
and blood. Nat Rev Neurol. Nature Publishing Group; 2013;9(4):201–10.  
13.  Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in 
cerebrospinal fluid and serum of patients with severe traumatic brain injury: Relationship to IL-6, 
TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol. 1999;101(2):211–21.  
14.  Carlson SL, Parrish ME, Springer JE, Doty K, Dossett L. Acute inflammatory response in spinal cord 
following impact injury. Exp Neurol. 1998;151(1):77–88.  
15.  Trivedi A, Olivas AD, Noble-Haeusslein LJ. Inflammation and spinal cord injury: Infiltrating 
leukocytes as determinants of injury and repair processes. Clin Neurosci Res. 2006;6(5):283–92.  
16.  Biglari B, Swing T, Child C, Buchler A, Westhausser F, Bruckner T, et al. A pilot study on temporal 
changes in IL-1β and TNF-α serum levels after spinal cord injury: the serum level of TNF-α in acute 
SCI patients as a possible marker for neurological remission. Spinal Cord. 2015;53(7):510–4.  
17.  Janssen O, Qian J, Linkermann A, Kabelitz D. CD95 ligand--death factor and costimulatory 
molecule? Cell Death Differ. 2003;10(11):1215–25.  
18.  Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci. 2004;5(2):146–56.  
19.  Cole GJ, McCabe CF. Identification of a developmentally regulated keratan sulfate proteoglycan that 
inhibits cell adhesion and neurite outgrowth. Neuron. 1991;7(6):1007–18.  
20.  Katoh-Semba R, Matsuda M, Kato K, Oohira A. Chondroitin sulphate proteoglycans in the rat brain: 
candidates for axon barriers of sensory neurons and the possible modification by laminin of their 
actions. Eur J Neurosci. 1995;7(4):613–21.  
21.  Kastin AJ, Pan W. Targeting neurite growth inhibitors to induce CNS regeneration. Curr Pharm Des. 
2005;11(10):1247–53.  
22.  McKerracher L, David S, Jackson DL, Kottis V, Dunn RJ, Braun PE. Identification of myelin-
associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron. 
 35
1994;13(4):805–11.  
23.  Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, et al. Nogo-A is a 
myelinassociated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature. 
2000;403:434–9.  
24.  Fournier AE, GrandPre T, Strittmatter SM. Identification of a receptor mediating Nogo-66 inhibition 
of axonal regeneration. Nature. 2001;409(6818):341–6.  
25.  Wang KC, Koprivica V, Kim JA, Sivasankaran R, Guo Y, Neve RL, et al. Oligodendrocyte-myelin 
glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature. 2002;417(6892):941–
4.  
26.  Oertle T, van der Haar ME, Bandtlow CE, Robeva A, Burfeind P, Buss A, et al. Nogo-A inhibits 
neurite outgrowth and cell spreading with three discrete regions. J Neurosci. 2003;23(13):5393–406.  
27.  Wright KT, Masri W El, Osman A, Roberts S, Chamberlain G, Ashton BA, et al. Bone marrow 
stromal cells stimulate neurite outgrowth over neural proteoglycans (CSPG), myelin associated 
glycoprotein and Nogo-A. Biochem Biophys Res Commun. 2007;354(2):559–66.  
28.  Wright KT, Uchida K, Bara JJ, Roberts S, Masri W El, Johnson WEB. Spinal motor neurite 
outgrowth over glial scar inhibitors is enhanced by coculture with bone marrow stromal cells. Spine J. 
2014;14(8):1722–33.  
29.  Bradbury EJ, Moon LDF, Popat RJ, King VR, Bennett GS, Patel PN, et al. Chondroitinase ABC 
promotes functional recovery after spinal cord injury. Nature. 2002;416(6881):636–40.  
30.  Freund P, Wannier T, Schmidlin E, Bloch J, Mir A, Schwab ME, et al. Anti-Nogo-A antibody 
treatment enhances sprouting of corticospinal axons rostral to a unilateral cervical spinal cord lesion 
in adult macaque monkey. J Comp Neurol. 2007;502(4):644–59.  
31.  Zhao RR, Andrews MR, Wang D, Warren P, Gullo M, Schnell L, et al. Combination treatment with 
anti-Nogo-A and chondroitinase ABC is more effective than single treatments at enhancing functional 
recovery after spinal cord injury. Eur J Neurosci. 2013;38(6):2946–61.  
32.  Hayes KC, Hull TCL, Delaney GA, Potter PJ, Sequeira KAJ, Campbell K, et al. Elevated serum titers 
of proinflammatory cytokines and CNS autoantibodies in patients with chronic spinal cord injury. J 
 36
Neurotrauma. 2002;19(6):753–61.  
33.  Marquardt G, Setzer M, Theisen A, Tews D-S, Seifert V. Experimental subacute spinal cord 
compression: correlation of serial S100B and NSE serum measurements, histopathological changes, 
and outcome. Neurol Res. 2011;33(4):421–6.  
34.  Shaw G, Yang C, Ellis R, Anderson K, Mickle JP, Scheff S, et al. Hyperphosphorylated 
neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun. 
2005;336(4):1268–77.  
35.  Ungureanu D, M IS, Dimitriu C, Iencean AS, Tascu A. Determination of the phosphorylated 
neurofilament subunit NF-H (pNF-H) in cerebro-spinal fluid as biomarker in acute traumatic spinal 
cord injuries. Rev Rom Med Lab. 2014;22(3):377–87.  
36.  Crutchfield CA, Thomas SN, Sokoll LJ, Chan DW. Advances in mass spectrometry-based clinical 
biomarker discovery. Clin Proteomics. 2016;13(1).  
37.  Light M, Minor KH, DeWitt P, Jasper KH, Davies SJ. Multiplex array proteomics detects increased 
MMP-8 in CSF after spinal cord injury. J Neuroinflammation. 2012;9(1):122.  
38.  Hachisuka S, Kamei N, Ujigo S, Miyaki S, Yasunaga Y, Ochi M. Circulating microRNAs as 
biomarkers for evaluating the severity of acute spinal cord injury. Spinal Cord. 2014;52(8):596–600.  
39.  Sengupta MB, Basu M, Iswarari S, Mukhopadhyay KK, Sardar KP, Acharyya B, et al. CSF 
Proteomics of Secondary Phase Spinal Cord Injury in Human Subjects: Perturbed Molecular 
Pathways Post Injury. PLoS One. 2014;9(10):e110885.  
40.  Lubieniecka JM, Streijger F, Lee JHT, Stoynov N, Liu J, Mottus R, et al. Biomarkers for Severity of 
Spinal Cord Injury in the Cerebrospinal Fluid of Rats. PLoS One. 2011;6(4):e19247.  
41.  Moghieb A, Bramlett H, Das J, Yang Z, Selig T, Yost R, et al. Differential neuroproteomic and 
systems biology analysis of spinal cord injury. Mol Cell Proteomics. 2016;15(7):2379–95.  
42.  Xu D, Omura T, Masaki N, Arima H, Banno T, Okamoto A, et al. Increased arachidonic acid-
containing phosphatidylcholine is associated with reactive microglia and astrocytes in the spinal cord 
after peripheral nerve injury. Sci Rep. 2016;6:26427.  
43.  Dunn WB. Mass spectrometry in systems biology an introduction. Methods Enzymol. 
 37
2011;500(1):15–35.  
44.  Peng J, Zeng J, Cai B, Yang H, Cohen M, Chen W, et al. Establishment of quantitative severity 
evaluation model for spinal cord injury by metabolomic fingerprinting. PLoS One. 2014;9(4):93736.  
45.  Vijayaprakash KM, Sridharan N. An experimental spinal cord injury rat model using customized 
impact device: A cost-effective approach. J Pharmacol Pharmacother. 2013;4(3):211–3.  
46.  Koozekanani SH, Vise WM, Hashemi RM, McGhee RB. Possible mechanisms for observed 
pathophysiological variability in experimental spinal cord injury by the method of Allen. J Neurosurg. 
1976;44(1):429–34.  
47.  Zhang N, Fang M, Chen H, Gou F, Ding M. Evaluation of spinal cord injury animal models. Neural 
Regen Res. 2014;9(22):2008–12.  
48.  Gruner JA, Yee AK, Blight AR. Histological and functional evaluation of experimental spinal cord 
injury: Evidence of a stepwise response to graded compression. Brain Res. 1996;729(1):90–101.  
49.  Onifer SM, Rabchevsky AG, Scheff SW. Rat models of traumatic spinal cord injury to assess motor 
recovery. ILAR J. 2007;48(4):385–95.  
50.  Xu XM, Chen A, Guénard V, Kleitman N, Bunge MB. Bridging Schwann cell transplants promote 
axonal regeneration from both the rostral and caudal stumps of transected adult rat spinal cord. J 
Neurocytol. 1997;26(1):1–16.  
51.  Fouad K, Schnell L, Bunge MB, Schwab ME, Liebscher T, Pearse DD. Combining Schwann Cell 
Bridges and Olfactory-Ensheathing Glia Grafts with Chondroitinase Promotes Locomotor Recovery 
after Complete Transection of the Spinal Cord. 2005;25(5):1169–78.  
52.  Miller CCJ, Ackerley S, Brownlees J, Grierson AJ, Jacobsen NJO, Thornhill P. Axonal transport of 
neurofilaments in normal and disease states. Cellular and Molecular Life Sciences. 2002. p. 323–30.  
53.  Al-Chalabi A, Miller CCJ. Neurofilaments and neurological disease. BioEssays. 2003. p. 346–55.  
54.  Gaiottino J, Norgren N, Dobson R, Topping J, Nissim A, Malaspina A, et al. Increased Neurofilament 
Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS One. 2013;8(9).  
55.  Kuhle J, Malmestrom C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, et al. Neurofilament light 
and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand. 
 38
2013;128(6):e33–6.  
56.  Trentini A, Comabella M, Tinotore M, Koel-Simmelink, M J Killestein J, Roos B, Rovira A, et al. N-
acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms 
of multiple sclerosis. J Neurol. 2014;261(12):2338–43.  
57.  Weydt P, Oeckl P, Huss A, M??ller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in 
asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. John Wiley and 
Sons Inc.; 2016;79(1):152–8.  
58.  Cai JY, Lu C, Chen MH, Ba HJ, Chen XD, Lin JH, et al. Predictive value of phosphorylated axonal 
neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage. Clin 
Chim Acta. 2013;424:182–6.  
59.  Millecamps S, Gowing G, Corti O, Mallet J, Julien JP. Conditional NF-L transgene expression in 
mice for in vivo analysis of turnover and transport rate of neurofilaments. J Neurosci. 
2007;27(1):4947–56.  
60.  Yuan A, Sasaki T, Rao M V, Kumar A, Kanumuri V, Dunlop DS, et al. Neurofilaments form a highly 
stable stationary cytoskeleton after reaching a critical level in axons. J Neurosci. 2009;29(36):11316–
29.  
61.  Ueno T, Ohori Y, Ito J, Hoshikawa S, Yamamoto S, Nakamura K, et al. Hyperphosphorylated 
neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury. 
Spinal Cord. Nature Publishing Group; 2011;49(3):333–6.  
62.  Nishida H, Nakayama M, Tanaka H, Kamishina H, Izawa T, Hatoya S, et al. Evaluation of serum 
phosphorylated neurofilament subunit NF-H as a prognostic biomarker in dogs with thoracolumbar 
intervertebral disc herniation. Vet Surg. Blackwell Publishing Inc.; 2014;43(3):289–93.  
63.  Ahadi R, Khodagholi F, Daneshi A, Vafaei A, Mafi AA, Jorjani M. Diagnostic Value of Serum 
Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of 
Human Traumatic Spinal Cord Injury. Spine (Phila Pa 1976). 2015;40(14):E823–30.  
64.  Guéz M, Hildingsson C, Rosengren L, Karlsson K, Toolanen G. Nervous tissue damage markers in 
cerebrospinal fluid after cervical spine injuries and whiplash trauma. J Neurotrauma. 2003;20(9):853–
 39
8.  
65.  Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, et al. Serum neurofilament 
light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg 
Psychiatry. 2015;86:273–9.  
66.  Brandt R, Lee G. The balance between tau protein’s microtubule growth and nucleation activities: 
implications for the formation of axonal microtubules. J Neurochem. 1993;61:997–1005.  
67.  Wang JZ, Liu F. Microtubule-associated protein tau in development, degeneration and protection of 
neurons. Prog Neurobiol. 2008;85(2):148–75.  
68.  Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW. A protein factor essential for microtubule 
assembly. Proc Natl Acad Sci U S A. 1975;72(5):1858–62.  
69.  Drubin DG, Kirschner MW. Tau protein function in living cells. J Cell Biol. 1986;103(6):2739–46.  
70.  K B. CSF biomarkers for mild cognitive impairment. J Intern Med. 2004;256:224–34.  
71.  Roerig A, Carlson R, Tipold A, Stein VM. Cerebrospinal fluid tau protein as a biomarker for severity 
of spinal cord injury in dogs with intervertebral disc herniation. Vet J. 2013;197(2):253–8.  
72.  Kwon BK, Stammers AMT, Belanger LM, Bernardo A, Chan D, Bishop CM, et al. Cerebrospinal 
fluid inflammatory cytokines and biomarkers of injury severity in acute human spinal cord injury. J 
Neurotrauma. 2010;27(4):669–82.  
73.  Kwon BK, Streijger F, Fallah N, Noonan VK, Belanger LM, Ritchie L, et al. Cerebrospinal Fluid 
Biomarkers To Stratify Injury Severity and Predict Outcome in Human Traumatic Spinal Cord Injury. 
J Neurotrauma. 2016;33:1–14.  
74.  Rech TH, Vieira SR, Nagel F, Brauner JS, Scalco R. Serum neuron-specific enolase as early predictor 
of outcome after in-hospital cardiac arrest: a cohort study. Crit Care. 2006;10(5):R133.  
75.  Tiainen M, Roine RO, Pettilä V, Takkunen O. Serum neuron-specific enolase and S-100B protein in 
cardiac arrest patients treated with hypothermia. Stroke. 2003;34(12):2881–6.  
76.  Cao F, Yang X, Liu W, Hu W, Li G, Zheng X, et al. Elevation of neuron-specific enolase and S-
100beta protein level in experimental acute spinal cord injury. J Clin Neurosci. 2008;15(5):541–4.  
77.  Loy DN, Sroufe AE, Pelt JL, Burke DA, Cao QL, Talbott JF, et al. Serum biomarkers for 
 40
experimental acute spinal cord injury: rapid elevation of neuron-specific enolase and S-100beta. 
Neurosurgery. 2005;56(2):391–7.  
78.  Wolf H, Krall C, Pajenda G, Leitgeb J, Bukaty AJ, Hajdu S, et al. Alterations of the biomarker S-
100B and NSE in patients with acute vertebral spine fractures. Spine J. 2014;14:2918–22.  
79.  Marchi N, Rasmussen P, Kapural M, Fazio V, Kight K, Mayberg MR, et al. Peripheral markers of 
brain damage and blood-brain barrier dysfunction. Restor Neurol Neurosci. 2003;21(3-4):109–21.  
80.  Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, et al. S100B’s double life: Intracellular 
regulator and extracellular signal. Biochim Biophys Acta - Mol Cell Res. 2009;1793(6):1008–22.  
81.  Ma J, Novikov LN, Karlsson K, Kellerth JO, Wiberg M. Plexus avulsion and spinal cord injury 
increase the serum concentration of S-100 protein: an experimental study in rats. 
ScandJPlastReconstrSurgHand Surg. 2001;35:355–9.  
82.  Diaz-Arrastia R, Wang KKW, Papa L, Sorani MD, Yue JK, Puccio AM, et al. Acute Biomarkers of 
Traumatic Brain Injury: Relationship between Plasma Levels of Ubiquitin C-Terminal Hydrolase-L1 
and Glial Fibrillary Acidic Protein. J Neurotrauma. 2014;31(1):19–25.  
83.  Yokobori S, Zhang Z, Moghieb A, Mondello S, Gajavelli S, Dietrich WD, et al. Acute Diagnostic 
Biomarkers for Spinal Cord Injury: Review of the Literature and Preliminary Research Report. World 
Neurosurg. 2015;83:867–78.  
84.  Davies AL, Hayes KC, Dekaban GA. Clinical Correlates of Elevated Serum Concentrations of 
Cytokines and Autoantibodies in Patients With Spinal Cord Injury. Arch Phys Med Rehabil. 
2007;88(11):1384–93.  
85.  Hasturk A, Atalay B, Calisaneller T, Ozdemir O, Oruckaptan H, Altinors N. Analysis of serum pro-
inflammatory cytokine levels after rat spinal cord ischemia/reperfusion injury and correlation with 
tissue damage. Turk Neurosurg. 2009;19(4):353–9.  
86.  Wang CX, Olschowka JA, Wrathall JR. Increase of interleukin-1beta mRNA and protein in the spinal 
cord following experimental traumatic injury in the rat. Brain Res. 1997;759(2):190–6.  
87.  Zhang N, Yin Y, Xu SJ, Wu YP, Chen WS. Inflammation & apoptosis in spinal cord injury. Indian 
Journal of Medical Research. 2012. p. 287–96.  
 41
88.  Shudo K, Kinoshita K, Imamura R, Fan H, Hasumoto K, Tanaka M, et al. The membrane-bound but 
not soluble form of human Fas ligand is responsible for its inflammatory activity. Eur J Immunol. 
2001;31(8):2504–11.  
89.  Biglari B, Buchler A, Swing T, Biehl E, Roth HJ, Bruckner T, et al. Increase in soluble CD95L 
during subacute phases after human spinal cord injury: a potential therapeutic target. Spinal Cord. 
2013;51(1):183–7.  
90.  Biglari B, Buchler A, Swing T, Child C, Biehl E, Reitzel T, et al. Serum sCD95L concentration in 
patients with spinal cord injury. J Int Med Res. 2015;43(2):250–6.  
91.  Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, et al. Serum neurofilament 
light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg 
Psychiatry. 2015;86(3):273–9.  
92.  Eng RH, Seligman SJ. Lumbar puncture-induced meningitis. JAMA. 1981;245(14):1456–9.  
93.  Greco I, Day N, Riddoch-Contreras J, Reed J, Soininen H, Kłoszewska I, et al. Alzheimer’s disease 
biomarker discovery using in silico literature mining and clinical validation. J Transl Med. 
2012;10(1):217.  
 
